SPIA
XLO icon

Steward Partners Investment Advisory’s Xilio Therapeutics XLO Stock Holding History

Steward Partners Investment Advisory’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,429
Closed -$14.5K – 4258
2025
Q1 		$14.5K Hold
1,429
– – ﹤0.01% 2937
2024
Q4 		$19.1K Hold
1,429
– – ﹤0.01% 2823
2024
Q3 		$15.8K Buy
+1,429
New +$17.5K ﹤0.01% 2758

Other funds holding XLO

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Steward Partners Investment Advisory's XLO Position: Q2 2025 in Review

Steward Partners Investment Advisory sold out of Xilio Therapeutics (XLO) in Q2 2025, closing a stake of 1,429 shares — an estimated $14.5K sold.

Steward Partners Investment Advisory first reported a position in XLO in Q3 2024 and held it in 3 quarters. The position peaked at $19.1K in Q4 2024. 35 funds tracked by Wall St. Rank hold XLO as of Q2 2025.

  • Steward Partners Investment Advisory reported no remaining Xilio Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 1,429 Xilio Therapeutics shares in Q2 2025, an estimated $14.5K.
  • Steward Partners Investment Advisory first reported a position in Xilio Therapeutics in Q3 2024 and held it in 3 quarters.
  • Steward Partners Investment Advisory's Xilio Therapeutics position peaked at $19.1K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2025.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2025, filed 12 Aug 2025.